title: Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
abstract: OBJECTIVE
  We aimed to confirm the efficacy of fulvestrant in Japanese postmenopausal advanced/recurrent breast cancer (ABC) patients, and investigate factors contributing to time-to-treatment failure (TTF) prolongation.
  
  
  METHODS
  This retrospective study included 194 ABC patients who received fulvestrant (500 mg) from January 2012 to December 2014.
  
  
  METHODS
  TTF (efficacy measure), overall survival (OS), factors prolonging TTF and adverse events were evaluated.
  
  
  RESULTS
  The median age was 65 (42 - 90) years. Overall, TTF was 5.48 months. In patients without prior chemotherapy (n = 59), OS was significantly longer (p = 0.0131) than in patients with prior chemotherapy (n = 135). There was no strong correlation between TTF with fulvestrant and other endocrine therapies, total duration of endocrine therapy and maximum duration of endocrine therapy. TTF was significantly longer in patients with less than two prior chemotherapy regimens (p = 0.0093), de novo metastatic disease (p = 0.0124) and without liver metastasis (p = 0.0024). We observed one case each of pulmonary infarction and psychiatric disorder.
  
  
  CONCLUSIONS
  Fulvestrant is effective for ABC patients and may show greater efficacy in patients with few prior chemotherapy regimens, de novo metastatic disease and absence of liver metastasis. Prior endocrine therapy duration might not be a predictive factor for fulvestrant TTF in heavily treated ABC patients.
authors.affiliation: a Breast Medical Oncology , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-1 Ariake, Koto-ku, Tokyo 135-8550 , Japan.|b Breast Oncology Center , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Araki
authors.affiliation: a Breast Medical Oncology , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-1 Ariake, Koto-ku, Tokyo 135-8550 , Japan.|b Breast Oncology Center , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Ishida
authors.affiliation: c Division of Pathology , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.|d Division of Pathology , The Cancer Institute of the Japanese Foundation for Cancer Research , Tokyo , Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Horii
authors.affiliation: e Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo , Japan.
authors.forename: Shunji
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: c Division of Pathology , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.|d Division of Pathology , The Cancer Institute of the Japanese Foundation for Cancer Research , Tokyo , Japan.
authors.forename: Futoshi
authors.initials: F
authors.lastname: Akiyama
authors.affiliation: a Breast Medical Oncology , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-1 Ariake, Koto-ku, Tokyo 135-8550 , Japan.|b Breast Oncology Center , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ito
authors.affiliation: b Breast Oncology Center , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.|f Breast Surgical Oncology , The Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D017698:Postmenopause; D012189:Retrospective Studies; D061665:Time-to-Treatment
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000077267:Fulvestrant; D004958:Estradiol
keywords: Japan; chemotherapy; fulvestrant; liver metastases; postmenopausal advanced/recurrent breast cancer; time-to-treatment failure